RLMD
Relmada Therapeutics Steers Course for a Promising Future
In a recent conference call, Relmada Therapeutics provided an update on its fourth quarter and full year 2025 financial results. The company reported significant progress in its lead program, NDV-01, which is being developed for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). According to Dr. Sergio Traversa, Relmada'